# A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)

> **NCT06741228** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Definium Therapeutics US, Inc.** · enrollment: 214 (actual)

## Conditions studied

- Generalized Anxiety Disorder

## Interventions

- **OTHER:** Placebo
- **DRUG:** MM120 (LSD D-Tartrate)

## Key facts

- **NCT ID:** NCT06741228
- **Lead sponsor:** Definium Therapeutics US, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-11
- **Primary completion:** 2026-05
- **Final completion:** 2026-11
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06741228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06741228, "A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06741228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*